Metformin Global Regulatory Status: FDA Approval, International Labels, and Post-Market Safety

FDA Approval Timeline and Original Indication

Metformin reached the U.S. market on December 29, 1994, when the FDA approved Bristol-Myers Squibb's New Drug Application (NDA 020357) for Glucophage. The approval came decades after the drug's initial synthesis in 1922 and its first clinical use in France during the 1950s [1]. The FDA's delay reflected long-standing concerns about phenformin, a related biguanide withdrawn in 1977 for causing fatal lactic acidosis at rates of roughly 40 to 64 cases per 100,000 patient-years [2].

The key U.S. registration trials enrolled approximately 900 patients with type 2 diabetes and demonstrated that metformin reduced fasting plasma glucose by 53 to 74 mg/dL compared with placebo, with concurrent HbA1c reductions of 1.4 to 1.8 percentage points [3]. Bristol-Myers Squibb's original label carried a contraindication for renal impairment defined by serum creatinine thresholds (≥1.5 mg/dL in men, ≥1.4 mg/dL in women) rather than estimated glomerular filtration rate. That threshold would remain unchanged for over two decades.

The UKPDS 34 trial, published in The Lancet in 1998, provided the evidence that cemented metformin's place as first-line therapy. Among 1,704 overweight patients with newly diagnosed type 2 diabetes, metformin monotherapy reduced diabetes-related death by 42% compared with conventional diet therapy (P = 0.017) and all-cause mortality by 36% (P = 0.011) [4]. No other oral antidiabetic agent had demonstrated a mortality benefit in a randomized trial at that time. The American Diabetes Association (ADA) subsequently recommended metformin as first-line pharmacotherapy in its Standards of Medical Care, a position it has maintained in every annual update through 2026 [5].

European and International Regulatory History

Metformin's regulatory life outside the United States predates its FDA approval by nearly four decades. Jean Sterne published the first clinical report on metformin (marketed as Glucophage) in France in 1957 [6]. French regulatory authorities approved the drug that same year, and approvals across Western Europe followed throughout the 1960s. The United Kingdom authorized metformin in 1958, making it available through the National Health Service years before the U.S. had even begun formal review.

The European Medicines Agency (EMA) does not hold a single centralized marketing authorization for metformin, because the drug predates the centralized procedure established in 1995. Instead, metformin is authorized through national procedures across all 27 EU member states [7]. The EMA has, however, issued scientific opinions affecting metformin labeling. A 2016 Pharmacovigilance Risk Assessment Committee (PRAC) review recommended harmonizing the renal contraindication across Europe to align with eGFR-based thresholds, a change that mirrored the concurrent FDA label revision [8].

The World Health Organization added metformin to its Model List of Essential Medicines in 1999. That list now reaches over 150 countries that use it as a benchmark for national formularies [9]. Metformin appears in treatment guidelines issued by Diabetes Australia, the Canadian Diabetes Association, the Japanese Diabetes Society, and the Indian Council of Medical Research. Each of these agencies positions metformin as first-line oral therapy for type 2 diabetes in adults without contraindications.

The 2016 Boxed Warning Revision: Expanding Renal Eligibility

The most significant U.S. labeling change since approval came on April 8, 2016, when the FDA issued a Drug Safety Communication revising metformin's renal contraindication. The agency replaced the outdated serum creatinine thresholds with eGFR-based criteria: metformin is now contraindicated only when eGFR falls below 30 mL/min/1.73 m², and initiation is not recommended between 30 and 45 mL/min/1.73 m² [10].

The revision drew on a systematic evidence review that examined 65 observational studies and pharmacokinetic analyses. The FDA concluded that the prior creatinine-based cutoffs had excluded hundreds of thousands of patients who could safely benefit from the drug. Dr. Rosebraugh, then Director of the Office of Drug Evaluation II at CDER, stated in the safety communication: "Based on our review, we are requiring labeling changes for metformin-containing medicines to reflect updated recommendations on its use in certain patients with reduced kidney function" [10].

This change was clinically meaningful. A 2018 analysis published in JAMA Internal Medicine estimated that the revised labeling expanded metformin eligibility to approximately 1.6 million additional U.S. adults with type 2 diabetes and moderate renal impairment (eGFR 30 to 60 mL/min/1.73 m²) [11]. The practical effect: clinicians no longer needed to discontinue metformin in patients with stage 3b chronic kidney disease unless eGFR dropped below 30 mL/min/1.73 m². The ADA's 2017 Standards of Care adopted these thresholds, and the Kidney Disease: Improving Global Outcomes (KDIGO) 2020 guideline endorsed continued metformin use down to eGFR 30 [12].

Lactic acidosis remains listed as a boxed warning. The current FDA-approved label states that the estimated incidence is approximately 6.3 cases per 100,000 patient-years [3]. A 2010 Cochrane review of 347 comparative trials and cohort studies found no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use [13]. The Endocrine Society's 2019 position statement noted: "The risk of metformin-associated lactic acidosis has been substantially overestimated historically, and the absolute risk in patients with eGFR above 30 mL/min/1.73 m² is exceedingly low" [14].

NDMA Impurity Investigation and Recalls

In December 2019, the FDA announced it was investigating N-nitrosodimethylamine (NDMA) contamination in metformin products, following alerts from international agencies. NDMA is classified as a probable human carcinogen. Singapore's Health Sciences Authority had detected NDMA above acceptable intake limits in certain metformin formulations earlier that year [15].

The FDA set an interim acceptable daily intake limit of 96 nanograms of NDMA per day for metformin products, consistent with the agency's approach to other NDMA-affected drugs such as valsartan and ranitidine [16]. Between February and June 2020, the FDA requested voluntary recalls of specific lots of extended-release metformin from manufacturers including Apotex Corp., Amneal Pharmaceuticals, Teva Pharmaceuticals, and Lupin Pharmaceuticals after laboratory testing confirmed NDMA levels exceeding the 96 ng limit [16].

Immediate-release metformin formulations were largely unaffected. The FDA's ongoing testing through its Sentinel System found that most immediate-release products contained NDMA levels well below the acceptable threshold. By late 2020, the FDA had completed testing of all marketed metformin products in the U.S. and confirmed that the contamination issue was confined primarily to specific extended-release formulations from specific manufacturers [17].

The agency emphasized that patients should not stop taking metformin without consulting their prescribers, given that the cardiovascular and glycemic risks of uncontrolled diabetes far outweighed the low incremental cancer risk from NDMA exposure at the levels detected. No metformin products were removed from the market permanently. Affected manufacturers reformulated or re-tested lots, and compliant extended-release products remain widely available.

Current Label: Indications, Contraindications, and Dosing

The FDA-approved prescribing information for metformin hydrochloride (revised through 2024) lists one indication: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes [3].

Key elements of the current label include:

Contraindications. Severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis including diabetic ketoacidosis, and known hypersensitivity to metformin [3].

Dosing. Immediate-release tablets start at 500 mg twice daily or 850 mg once daily, titrated in 500 mg increments every one to two weeks. Maximum recommended daily dose is 2,550 mg (immediate-release) or 2,000 mg (extended-release). The label recommends checking eGFR before initiation and at least annually thereafter [3].

Renal monitoring. For patients with eGFR between 30 and 45 mL/min/1.73 m², the label advises against initiating metformin but permits continuation with more frequent renal monitoring if eGFR falls into that range during treatment. The label instructs prescribers to discontinue metformin if eGFR drops below 30 mL/min/1.73 m² [10].

Vitamin B12 monitoring. Long-term metformin use is associated with decreased vitamin B12 absorption. The Diabetes Prevention Program Outcomes Study found that after a median of 13 years of follow-up, 4.3% of metformin-treated participants developed low B12 levels compared with 2.3% on placebo [18]. The current label recommends periodic measurement of hematologic parameters and vitamin B12 at two- to three-year intervals.

Contrast dye precautions. The label was updated in 2017 to relax prior requirements for mandatory metformin discontinuation before all iodinated contrast procedures. The revised recommendation limits discontinuation to patients with eGFR between 30 and 60 mL/min/1.73 m², hepatic impairment, or those receiving intra-arterial contrast [3].

Post-Market Surveillance and Ongoing Safety Signals

The FDA Sentinel System, the agency's active post-market surveillance infrastructure, monitors metformin safety across a distributed data network covering over 100 million patients [19]. Sentinel analyses have evaluated signals for lactic acidosis, acute kidney injury, and B12 deficiency in real-world populations, consistently finding that the drug's benefit-risk profile remains favorable.

A 2020 Sentinel assessment examining metformin and acute kidney injury across 2.4 million new users found no statistically significant increase in AKI risk compared with sulfonylurea initiators after multivariable adjustment (hazard ratio 0.94, 95% CI 0.88 to 1.01) [19]. This finding reinforced the safety of the relaxed renal thresholds.

Outside the United States, the EMA's EudraVigilance database collects spontaneous adverse event reports from EU member states. Periodic safety update reports submitted by marketing authorization holders have not identified new safety signals requiring label changes beyond those already implemented for renal dosing and NDMA impurity limits [7].

Several regulatory agencies have also evaluated metformin in the context of off-label use for polycystic ovary syndrome (PCOS), gestational diabetes prevention, and cancer risk reduction. While no agency has approved metformin for these indications, the FDA has permitted investigational use under IND applications, and the National Cancer Institute has sponsored clinical trials (such as MA.32) evaluating metformin as adjuvant therapy in breast cancer [20].

Generic Availability and Global Access

Metformin's U.S. patent protection expired in 2002 (Glucophage immediate-release) and 2003 (Glucophage XR). The FDA's Orange Book currently lists over 30 approved abbreviated new drug applications (ANDAs) for metformin hydrochloride tablets and extended-release tablets across multiple manufacturers [21].

Generic competition has made metformin one of the least expensive prescription medications globally. The average U.S. wholesale acquisition cost for a 30-day supply of metformin 500 mg twice daily is under $4.00. In many low- and middle-income countries, metformin costs less than $1.00 per month through the WHO's prequalification programme and UNICEF supply channels [9].

In the United States alone, metformin accounted for over 90 million prescriptions in 2023, making it the fourth most prescribed medication overall [22]. This volume reflects both new initiations and the drug's long treatment durations. Many patients with type 2 diabetes remain on metformin for 10 to 20 years or longer, often in combination with newer agents such as SGLT2 inhibitors or GLP-1 receptor agonists.

The combination of strong trial evidence, low cost, established safety, and broad regulatory approval across more than 60 countries makes metformin a singular drug in modern endocrinology. No oral antidiabetic agent has a longer continuous post-market track record or wider global accessibility.

Regulatory Outlook: Ongoing and Future Considerations

Several regulatory developments may affect metformin's labeling and access in coming years. The Targeting Aging with Metformin (TAME) trial, a randomized controlled study of metformin for age-related disease prevention in non-diabetic adults aged 65 to 79, is underway with an expected enrollment of 3,000 participants across 14 U.S. centers [23]. If TAME demonstrates benefit, it could prompt an FDA supplemental NDA for a novel "aging-related" indication, a regulatory first.

The FDA's Nitrosamine Impurities Steering Committee continues to monitor NDMA levels across all metformin products and has required ongoing stability testing from manufacturers [16]. No new recalls have been issued since 2020, but the agency's risk assessment framework for nitrosamine impurities applies to all marketed formulations indefinitely.

In Europe, the EMA is reviewing whether to require standardized patient-friendly labeling across all metformin products authorized through national procedures, given the drug's use by tens of millions of patients who may switch between generic brands. The Pharmaceutical Strategy for Europe, adopted in 2020, prioritizes such harmonization for high-volume essential medicines [7].

The ADA's 2026 Standards of Care reaffirm metformin as the preferred initial pharmacotherapy for type 2 diabetes, to be started at diagnosis alongside lifestyle interventions, with the addition of agents having proven cardiovascular or renal benefit (GLP-1 RAs or SGLT2 inhibitors) based on individual patient comorbidities [5]. Metformin's regulatory position as the default first-line agent remains unchallenged across every major clinical guideline worldwide. Annual eGFR monitoring and periodic B12 assessment are the primary ongoing safety requirements for all patients on long-term therapy.